Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM

Video

Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
4 experts in this video
4 experts in this video
Related Content